mediluxjune06

Update June 2006

Since the beginning of the year Medilux Healthcare Ltd have expanded into a new market, adding to our Q.Light range of products and the ground breaking new Episcan Portable Tissue Scanner, recently introduced into the public and private healthcare market sectors. This update contains an overview of key developments during 2006. If you or any member of your team have any questions then please do not hesitate to contact me, Steven Warren, the author of this update via email at s.warren@timelinesuk.net or by post or phone at
No 1 Atlantic House, 128 Albert Street, London NW1 7NE telephone 0845 838 1560.

January 2006 saw Medilux Healthcare Ltd finalise an agreement with the European CyberKnife Centre (ECZM) in Munich, Germany, to represent them via press and media, as well as direct contact with all top specialists and specialist centres in the UK and Ireland. ECZM offers state of the art robotic radiosurgery treatment for a range of serious and debilitating medical conditions at their centre, attached to the University Hospital , Munich. They have special expertise and facilities for tumours in the central nervous system (brain and spine) but also treat patients with liver, pancreatic and lung cancer. In addition to cancer, cyberknife radiosurgery has had excellent results in the treatment of ateriovenous malformation [AVM], trigeminal neuralgia and acoustic neuroma. More information as to the exact nature of Cyberknife can be found from the homepage of our site and we are handling referrals from NHS and private hospital sectors.

June 6th saw a media roll out, now that top specialists have been informed of this useful option to traditional surgery and radiotherapy. As part of our awareness-building we have links to major cancer and other medical charities here in the UK. If you would like to learn more then visit the DOWNLOAD section of our website to read the latest press releases.

Our recent direct mailings to some 600 specialist doctors and treatment centres throughout the UK have included Photodynamic Therapy [PDT]. This uses defined spectrum light with photosensitising cream for the treatment of skin cancer and other conditions, and we market both phototherapy devices and the Episcan portable ultrasound scanner [see below]. Given the excellent cosmetic results obtained from this form of treatment, PDT is now becoming widely accepted as an important alternative to traditional ablative and/or cryosurgery, particularly for skin cancer on the face and head. The PDT light system marketed by Medilux UK Ltd and our distributors includes blue and red filters. The blue filter, when combined with a special cream, provides an accurate assessment of the extent of the cancerous and pre cancerous sites and the red filter activates the special cream used to treat the cancer.

Christie Hospital, Manchester, is now using Episcan to advance their research into the accurate diagnosis and exploration of treatment options for skin cancer. Episcan portable tissue scanner is also of growing interest to general practitioners and local care centres, given the changes in care provision now taking shape in the UK in line with government directives. We continue to receive enquiries from various GP markets and are looking for distributors to extend our market penetration.

We now have enquiries from those researching the cosmetic market and in line with the Skin Care Inc article [copies on request] which relates to " Proving that an aesthetic procedure or products really works has evolved from the simple, “Please tell me all about it and show me before-and-after photographs,” to, “Do you have any studies proving what you are saying is true and accurate?”

One key area of success for phototherapy which is slow in developing here in the UK is the application to non-healing wounds such as venous leg ulceration. NICE [The National Institute of Clinical Excellence] is still waiting to process alternative treatments, other than traditional pressure and wound dressings, and patients are now demanding better care and choice. Clinical Director, Steven Warren, is exploring with medical practitioners in the private sector the use of Q.Light phototherapy for treatment in these areas, rather than relying on NHS care. Research findings from a Swiss nursing home clearly demonstrate the tremendous accelerated healing possible when applying phototherapy for just a few minutes during daily wound care procedures. Pictures and research are available from our clinical director by emailing s.warren@timelinesuk.net

Focusing on new research, findings have just been released of recent research studies conducted by Professor K Samilova and her team at The Russian Academy of Science in St Petersburg. These clearly demonstrate the effect of Q.Light on the whole body [termed the photomodulatory effect] as well as the beneficial direct biostimulation of body cells and tissue. If you wish to see details of this research then once again you are requested to contact our Clinical Director at s.warren@timelinesuk.net

If you no longer wish to receive our updates then please reply to this email with UNSUBSCRIBE in the subject and your email address will be immediately removed from our listing.

Steven Warren
Clinical Director
Medilux Healthcare Limited

Medilux Healthcare Limited is a specialised marketing company. We promote devices on the basis of the Manufacturers' representations as to quality and efficacy and where possible we provide additional information as to the conditions which may benefit from their use but we do not guarantee that they will be suitable or effective for all purchasers. We do not examine or diagnose patients or recommend treatments and where we promote medical services this is on an information-only basis. Patients contract directly with these providers and all clinical decisions are made by them alone.